Maze Therapeutics, Inc. (MAZE) Reports Q1 Loss, Beats Revenue Estimates

Maze Therapeutics reported a quarterly loss of $0.45 per share, slightly wider than the Zacks Consensus Estimate loss of $0.43. The result was still a significant improvement from a loss of $1.15 per share in the same quarter last year. The print is mildly negative on a consensus basis, but the year-over-year earnings trend is better.

Analysis

Maze Therapeutics reported a quarterly loss of $0.45 per share, slightly wider than the Zacks Consensus Estimate loss of $0.43. The result was still a significant improvement from a loss of $1.15 per share in the same quarter last year. The print is mildly negative on a consensus basis, but the year-over-year earnings trend is better.